# Kellie N. Smith

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kellie-n-smith/

## Facts

| Field | Value |
| --- | --- |
| Citations | 14,281 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 31 |
| i10-index | 48 |
| Last Known Institution | Bloomberg (United States) |
| OpenAlex ID | https://openalex.org/A5082613510 |
| ORCID iD | 0000-0002-6295-8930 |
| Works | 239 |

## Researcher papers

- [Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade](https://scholariq.org/papers/mismatch-repair-deficiency-predicts-response-of-solid-tumors-to-pd-1-blockade/)
- [Neoadjuvant PD-1 Blockade in Resectable Lung Cancer](https://scholariq.org/papers/neoadjuvant-pd-1-blockade-in-resectable-lung-cancer/)
- [Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer](https://scholariq.org/papers/evolution-of-neoantigen-landscape-during-immune-checkpoint-blockade-in-non-small/)
- [Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)](https://scholariq.org/papers/pathologic-features-of-response-to-neoadjuvant-anti-pd-1-in-resected-non-small/)
- [Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers](https://scholariq.org/papers/transcriptional-programs-of-neoantigen-specific-til-in-anti-pd-1-treated-lung/)
- [Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer](https://scholariq.org/papers/neoadjuvant-nivolumab-plus-ipilimumab-in-resectable-non-small-cell-lung-cancer/)
- [Redundant Innate and Adaptive Sources of IL17 Production Drive Colon Tumorigenesis](https://scholariq.org/papers/redundant-innate-and-adaptive-sources-of-il17-production-drive-colon/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [Bloomberg (United States)](https://scholariq.org/institutions/bloomberg-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.